Gene Editing · eu
Repairing Patients’ Own Hematopoietic Stem Cells: Prime Editing Offers Clues to Treating GATA2 Deficiency
Researchers corrected a disease-causing variant in patient-derived cells, increasing the proportion of functional gene copies and observing improved engraftment potential. Scaling up production and validating safety remain necessary before moving toward autologous cell therapy.
For patients with GATA2 deficiency, the root of their shortage of immune cells lies in the stem cells that produce blood cells. A team at Aarhus University in Denmark has now used prime editing to repair a disease-causing variant in patient-derived hematopoietic cells, providing preclinical evidence for eventually using patients’ own cells to restore blood formation and immune function. The study, conducted by Jonas Holst Wolff, Jacob Giehm Mikkelsen and colleagues, was published in *Science Translational Medicine* on September 30.
GATA2 is a transcription factor that regulates gene expression. Patients carry one normal and one disease-causing copy of the gene, which may leave them unable to produce enough immune cells. The team used prime editing, a technology derived from CRISPR that can rewrite DNA sequences according to a specified design without completely severing both DNA strands. For cells that need to retain long-term blood-forming capacity, minimizing damage caused by editing is just as critical as repairing the gene.
The study targeted the GATA2 c.956_962del variant in patients’ CD34-positive hematopoietic stem and progenitor cells. According to the paper’s abstract, editing efficiency reached up to 70%, while the proportion of functional GATA2 alleles increased from 50% to 77%. These are two different measures: the former describes editing efficiency, while the latter describes the proportion of normal gene copies. Neither can be directly interpreted as a treatment success rate for patients.
The university’s report stated that the function of the relevant protein improved in the edited cells. The paper’s abstract also showed that these cells had better transplantation engraftment potential than untreated cells. Safety analyses detected limited genotoxicity at the target site and found no editing at the 20 highest-ranked predicted off-target sites. These results provide preliminary support, but the scope of testing was limited and is not yet sufficient to rule out all unintended changes or long-term risks.
The related sequencing data have been registered in the European Genome-phenome Archive, with 13 samples listed, using Illumina and Oxford Nanopore platforms. This figure represents the number of samples in the dataset and cannot be taken as the number of patients studied. Access to the raw sequencing data from patients’ stem cells for analysis also requires procedures including ethics review and institutional agreements.
In addition to repairing this specific variant, the team tested a strategy called PASSIGE in hematopoietic stem and progenitor cells, combining prime editing with site-specific integration technology to insert complementary DNA. The idea behind this approach is to give treatment designs the potential to cover a wider range of disease-causing GATA2 variants. It remains a preclinical exploration and has not yet been shown to be broadly applicable to patients.
The next hurdle on the path to treatment is scale. According to the university, researchers must demonstrate that the method can handle the number of cells required for autologous transplantation, far more than in the current experiments, and determine which patients are most likely to benefit. Some patients with GATA2 deficiency can currently receive donor hematopoietic stem cell transplants. The concept of using their own repaired cells requires further development. The findings demonstrate that repair is possible; whether it can deliver lasting improvements in immune function remains a question for further research.